Active Ingredient:
Nicotine 21mg, 14mg or 7mg

Description:
Transdermal clear patch in 3 strengths (sizes)

Other Ingredients:
Drug Reservoir:  Ethylene Vinyl Acetate Copolymer
Occlusive Backing: Polyethylene Terephthalate/ Ethylene vinyl acetate
Rate Controlling Membrane:  Polyethylene Film
Contact Adhesive:  Polyisobutylene B100 and B12 SFN
Protective Layer:  Siliconised Polyester Film
Printing Ink: White ink

Indications:
NiQuitin is indicated for the relief of nicotine withdrawal symptoms including cravings as an aid to smoking cessation. If possible, when stopping smoking, NiQuitin Clear should be used in conjunction with a behavioural support programme.

Contraindications:
NiQuitin is contraindicated in patients with hypersensitivity to the system, the active substance, or any of the excipients.
NiQuitin patches should not be used by non-smokers, occasional smokers or children under 12 years.

Dosage:
Adults 18 years and over:
NiQuitin Clear patches should be applied once a day, at the same time each day and preferably soon after waking, to a non-hairy, clean, dry skin site and worn continuously for 24 hours. The NiQuitin patch should be applied promptly on removal from its protective sachet.

Avoid applying to any skin which is broken, red or irritated. After 24 hours the used patch should be removed and a new patch applied to a fresh skin site. The patch should not be left on for longer than 24 hours. Skin sites should not be reused for at least seven days. Only one patch should be worn at a time.

Patches may be removed before going to bed if desired. However use for 24 hours is recommended to optimise the effect against morning cravings.

NiQuitin therapy should usually begin with NiQuitin 21 mg and be reduced according to the following dosing schedule:-

Light smokers (e.g. those who smoke less than 10 cigarettes per day) are recommended to start at Step 2 (14 mg) for 6 weeks and decrease the dose to NiQuitin 7 mg for the final 2 weeks.

Patients on NiQuitin Clear 21mg who experience excessive side effects which do not resolve within a few days should change to NiQuitin Clear 14mg for the remainder of their first 6 weeks before stepping down to NiQuitin Clear 7mg for 2 weeks.

Tratement maybe continued beyond 10 weeks if needed, however consult a healthcare professional if using beyond 9 months.

Adolescents and children:
Adolescents (12 to 17 years) should follow the schedule of treatment for adults presented above for steps 1, 2 and 3, but as data are limited, duration of NRT in this age group is restricted to 12 weeks. If longer treatment is required advice from a healthcare professional should be sought.

NiQuitin is not recommended for use in children under 12 years of age.

Legal Status:
GSL

Available In:
21mg 7 and 14 patches, 14mg 7 patches, 7mg 7 patches

Click here for full product information